Laurus Labs adds Rs 40,150 crore to investors' wealth in a year with 120% rally. Buy, hold or book profits?Laurus Labs has significantly boosted investor wealth, adding over Rs 40,000 crore in a year with a 120% stock rally. Driven by business im...
Wockhardt shares jump 9% after strong Q4 turnaround, robust FY26 growthWockhardt shares saw a significant jump on Tuesday. The pharmaceutical company reported a strong turnaround in its March quarter performanc...
Sun Pharma deal: Perception changer for Indian pharma sector? 10 pharma stocks with upside potential of up to 38%The Indian pharma sector made its initial global forays almost a quarter century ago. Companies sought out markets abroad, learnt to deal w...
Stock picks of the week: 5 stocks with consistent score improvement and upside potential of up to 33%To get clarity on the markets, there are three questions to which you need answers. First: When will the war end? Second: How long will it ...
US protects genuine investors in EB-5 green card programThe US Citizenship and Immigration Services (USCIS) has updated its policy manual to protect 'good faith' investors in the EB-5 program. Th...
Lupin to resize portfolio, slash costs in US biz turnaroundIn an interview to ET, CEO Vinita Gupta said the company had already exited a few products filed from its Somerset facility in New Jersey a...
Suven's new chemical entity enters clinical trial stage in USPharmaceutical firm Suven Life Sciences today said its new chemical entity (NCE) has entered the phase 1 of clinical trial in the US.
- Venus Remedies hits 52-week high on DCGI nod
Venus Remedies Ltd surged over 7 per cent in trade on Wednesday to hit its 52-week high of Rs 328.25 after the pharma company announced tha...
Venus gets DCGI nod for Phase-III of cancer detection entityIn a recent report, the World Health Organisation (WHO) has warned that there will be a cancer patient in each household in India by 2020.
- Textiles ministry grants Rs 24.5 crore to ICT to set up R&D centre
A textiles committee will assist ICT in organising seminars all over the country and collecting samples of various materials.
- Drug companies plan late-stage deals with MNCs
In a distinct shift in their new drug development strategy, Indian pharma majors such as Dr Reddy’s Lab (DRL), Nicholas Piramal, Wockhardt ...
- Glenmark gets domestic patent for NCE
In what is perhaps the first domestic patent for a new chemical entity (NCE) by an Indian company, drug research company Glenmark Pharmaceu...
- Pharma companies demerging NCE, NDDS operations
Pharma majors are de-merging their NCE operations into separate cos to scale-up their activities and achieve better focus. Drug cos in pric...
- Ranbaxy to hive off drug discovery research biz
Ranbaxy Laboratories has decided to hive off its drug discovery research (DDR) operation into a separate company and plans to list the new ...
- NPIL to invest Rs 300 cr in R&D unit
: Domestic pharma major Nicholas Piramal India (NPIL) has decided to invest some Rs 250-300 crore in the next two years in its recently dem...
- Ranbaxy first Indian pharma to launch NCE globally
Ranbaxy has completed the second phase of the clinical trial of a revolutionary anti- malarial drug.
- Indian pharma cos close to blockbuster breakthrough
Indian pharma majors may manage to market their first indi-genous "blockbuster drugs" or new chemical entities (NCEs) in the next four year...